Intermittent ethanol consumption depresses endocannabinoid-signaling in the dorsolateral striatum of rat

Neuropharmacology. 2011 Dec;61(7):1160-5. doi: 10.1016/j.neuropharm.2011.01.014. Epub 2011 Jan 18.

Abstract

Recent research suggests that adaptations elicited by drugs of abuse share common features with traditional learning models, and that drugs of abuse cause long-term changes in behavior by altering synaptic function and plasticity. In this study, endocannabinoid (eCB) signaling in the dorsolateral striatum, a brain region vital for habit formation, was evaluated in acutely isolated brain slices from ethanol (EtOH)-consuming rats and control rats. EtOH-consuming rats had free access to a 20% EtOH solution for three 24 hour sessions a week during seven weeks and consumed an average of 3.4 g/kg per session. eCB-mediated long-lasting disinhibition (DLL) of population spike (PS) amplitude induced by moderate frequency stimulation was impaired in EtOH-consuming rats, and was not restored by the muscarinic receptor antagonist scopolamine (10 μM). The lack of DLL could be linked to a reduced GABA(A) receptor tone, since bicuculline-mediated disinhibition of striatal output was significantly reduced in slices from EtOH-consuming rats. However, eCB signaling induced by high frequency stimulation (HFS) was also impaired in slices from EtOH-consuming rats and isolated control rats. Activation of presynaptic cannabinoid 1 receptors (CB1R) with WIN55,212-2 (250 nM, 1 μM) significantly modulated PS amplitude in slices from age-matched control rats while slices from EtOH-consuming rats remained unaffected, indicating that eCB signaling is inhibited at a level that is downstream from CB1R activation. Intermittent alcohol intake for seven weeks might thus be sufficient to modulate a presynaptic mechanism that needs to be synergized with CB1R activation for induction of long-term depression (LTD). In conclusion, alcohol consumption inhibits striatal eCB signaling in a way that could be of importance for understanding the neurological underpinnings of addictive behavior.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alcohol Drinking / adverse effects
  • Alcohol Drinking / metabolism*
  • Animals
  • Benzoxazines / pharmacology
  • Bicuculline / pharmacology
  • Cannabinoid Receptor Modulators / metabolism*
  • Corpus Striatum / drug effects*
  • Corpus Striatum / metabolism
  • Corpus Striatum / physiopathology
  • Endocannabinoids*
  • GABA-A Receptor Antagonists / pharmacology
  • In Vitro Techniques
  • Male
  • Morpholines / pharmacology
  • Muscarinic Antagonists / pharmacology
  • Naphthalenes / pharmacology
  • Nerve Tissue Proteins / agonists
  • Nerve Tissue Proteins / antagonists & inhibitors
  • Nerve Tissue Proteins / metabolism
  • Neural Inhibition / drug effects*
  • Neuronal Plasticity / drug effects
  • Neurons / drug effects*
  • Neurons / metabolism
  • Rats
  • Rats, Wistar
  • Receptor, Cannabinoid, CB1 / agonists
  • Receptor, Cannabinoid, CB1 / metabolism*
  • Scopolamine / pharmacology
  • Signal Transduction / drug effects*
  • Synaptic Potentials / drug effects

Substances

  • Benzoxazines
  • Cannabinoid Receptor Modulators
  • Cnr1 protein, rat
  • Endocannabinoids
  • GABA-A Receptor Antagonists
  • Morpholines
  • Muscarinic Antagonists
  • Naphthalenes
  • Nerve Tissue Proteins
  • Receptor, Cannabinoid, CB1
  • (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone
  • Scopolamine
  • Bicuculline